

Oncology Today with Dr Neil Love: BCMA-Directed Therapies for Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which response rate has been reported in the Phase II DREAMM-2 trial evaluating belantamab mafodotin for patients with relapsed/refractory multiple myeloma (MM)?
 - 11%
 - 32%
 - 45%
- What was the overall response rate with ciltacabtagene autoleucl (cilta-cel) after a median of 17.1 months of follow-up from Cohort A of the CARTITUDE-2 trial, evaluating this agent in patients with MM after 1 to 3 prior lines of therapy?
 - 35%
 - 55%
 - 75%
 - 95%
- Which of the following statements is true regarding the cytokine release syndrome (CRS) associated with CAR T-cell therapy in patients with MM treated with idecabtagene vicleucl (ide-cel) in the KarMMA-1 trial or cilta-cel in the CARTITUDE-1 trial?
 - The median time to onset of CRS was shorter with ide-cel
 - The incidence of any grade of CRS was higher with ide-cel
 - The incidence of Grade ≥ 3 CRS was higher with cilta-cel
 - The median duration of CRS was longer with cilta-cel
- In a recent report of the overall safety profile of teclistamab from the MajesTEC-1 trial for patients with relapsed/refractory MM, which of the following adverse events was most common?
 - Neutropenia
 - Injection site reaction
 - Fatigue
 - CRS
- Which of the following overall survival (OS) results was reported after long-term follow-up of the pivotal Phase II KarMMA trial evaluating ide-cel for relapsed/refractory MM?
 - Median OS was >20 months regardless of R-ISS stage
 - Median OS was longer for patients with triple-refractory disease than for patients whose disease was not triple refractory
 - Median OS was longer for patients aged ≥ 65 than for patients younger than 65
 - Median OS was shorter for patients with extramedullary disease than for those without extramedullary disease